← Back to Search

Cannabinoid

THC for Psychosis Risk

Phase < 1
Waitlist Available
Led By Mohini Ranganathan, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Having one relative with a confirmed psychotic disorder
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up -30 min, +240 min
Awards & highlights

Study Summary

This trial is testing whether people with a family history of psychosis react differently to THC than controls without a family history of psychosis.

Who is the study for?
This trial is for people who have tried cannabis at least once and are medically and mentally healthy. They must also have a relative with a confirmed psychotic disorder. It's not specified who can't join, but typically those with health issues that could interfere would be excluded.Check my eligibility
What is being tested?
The study aims to see if having a family history of psychosis affects how the body responds to THC, an active component of cannabis. Participants will receive either very low dose THC, low dose THC, or a placebo without knowing which one they're getting.See study design
What are the potential side effects?
While the document doesn't list specific side effects, typical reactions to THC may include altered senses or sense of time, mood changes, impaired body movement, difficulty thinking and problem-solving.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a family member with a confirmed psychotic disorder.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~-30 min, +15 min, +80 min, +150 min, +240 min
This trial's timeline: 3 weeks for screening, Varies for treatment, and -30 min, +15 min, +80 min, +150 min, +240 min for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
Secondary outcome measures
Clinician Administered Dissociative Symptoms Scale (CADSS)
Hopkins Verbal Learning Test (HVLT)
Psychotomimetic States Inventory (PSI)
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: No Family History of Psychosis (FHN)Experimental Treatment3 Interventions
Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions.
Group II: Family History of Psychosis (FHP)Experimental Treatment3 Interventions
Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,847 Previous Clinical Trials
2,736,507 Total Patients Enrolled
6 Trials studying Psychosis
3,035 Patients Enrolled for Psychosis
Mohini Ranganathan, MDPrincipal InvestigatorYale University
4 Previous Clinical Trials
88 Total Patients Enrolled

Media Library

Low Dose THC (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT02102113 — Phase < 1
Psychosis Research Study Groups: No Family History of Psychosis (FHN), Family History of Psychosis (FHP)
Psychosis Clinical Trial 2023: Low Dose THC Highlights & Side Effects. Trial Name: NCT02102113 — Phase < 1
Low Dose THC (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02102113 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the uppermost limit of subjects participating in this examination?

"This particular clinical trial has since ended, having first been posted on the 1st of January 2014 and last revised on July 21 2022. For those seeking other medical studies related to schizophrenia, 679 trials are open for enrollment while 38 different experiments pertaining to Low Dose THC are actively looking for participants."

Answered by AI

Is it possible for adults aged 35 or above to partake in this research?

"The enrollment criteria for this medical experiment necessitates that potential candidates must be aged 18 or older, and no more than 55."

Answered by AI

To whom does the qualifications for this trial pertain?

"Prospective participants should have a diagnosis of schizophrenia and be between the ages 18-55 to qualify for this trial. Approximately 21 patients are needed in total."

Answered by AI

Are there other investigations to evaluate the effects of Low Dose THC?

"Currently, 38 clinical trials are investigating the potential of Low Dose THC with 6 studies in Phase 3. These investigations centre around Belmont, Massachusetts however there are 90 other locations that have approved this type of testing."

Answered by AI

What ailments are alleviated by the administration of Low Dose THC?

"Low Dose THC can help address weight loss, inadequate response to traditional therapies, and pharmacotherapy."

Answered by AI

Are there any open enrollment slots for this medical experiment?

"This medical trial is not currently recruiting. It was posted on 1/1/2014 and last updated 7/21/2022; however, there are 679 other clinical trials for schizophrenia and 38 studies for Low Dose THC that are actively seeking participants."

Answered by AI

Who else is applying?

What state do they live in?
New York
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Probing the Cannabinoid System in Individuals With a Family History of Psychosis
Mohini Ranganathan 2014. "Probing the Cannabinoid System in Individuals With a Family History of Psychosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02102113.
All > Mental Illness > Cannabis
~0 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top